ArticleHealth science reports2026
Demographic and Clinical Insights Into Pyoderma Gangrenosum: A Retrospective Cross-Sectional Study From a Tertiary Care Hospital.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Demographic and Clinical Insights Into Pyoderma Gangrenosum: A Retrospective Cross-Sectional Study From a Tertiary Care Hospital.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Pyoderma gangrenosum (PG) is a rare, non-infectious inflammatory skin disease often associated with systemic disorders such as inflammatory bowel disease (IBD), malignancies, and autoimmune conditions. This study aimed to investigate the demographic characteristics, comorbidities, differential diagnoses, and treatment outcomes in patients with histopathologically confirmed PG at a tertiary referral hospital in Iran. Methods: This retrospective cross-sectional study included 58 patients diagnosed with PG at Rasool Akram Hospital between 2018 and 2023. Data were extracted from medical records and follow-up phone interviews. Variables included demographic information, smoking status, pathergy test results, underlying diseases, treatment regimens, and patient-reported satisfaction. Statistical analysis was performed using SPSS version 26. Results: Among the 58 patients, 53.4% were female, and the mean age was 55.88 ± 13.83 years. Underlying conditions were present in 46.6% of patients, most commonly IBD (29.3%), malignancy (15.5%), and rheumatoid arthritis (10.3%). The most prescribed medications were prednisolone (96.6%), methotrexate (51.7%), and cyclosporine (39.7%). Patient satisfaction was highest for etanercept (100%), infliximab (83.3%), and methotrexate (60.0%). No statistically significant associations were found between gender and smoking status or between comorbidities and pathergy test results. Conclusion: PG is frequently associated with systemic diseases, particularly IBD and malignancy, suggesting a syndromic relationship. Multidisciplinary evaluation is recommended for affected patients. Treatment satisfaction was highest for biologics and immunosuppressants, providing direction for future clinical management and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.